Cybin Inc. announced that the United States Patent and Trademark Office granted U.S. patent 12,291,499 in support of its CYB003 program for Major Depressive Disorder (MDD). This patent provides important validation for the program, which is currently in Phase 3 development.
The newly issued patent includes claims to pharmaceutical compositions and oral dosage forms within Cybin’s proprietary deuterated psilocin analog program, CYB003. This patent is expected to provide exclusivity until 2041, reinforcing the commercial potential of the pipeline.
Cybin's intellectual property portfolio continues to expand, now comprising more than 80 granted patents and over 230 pending applications. Robust patent protection is essential for drug development companies, and this addition strengthens Cybin's position as it continues to dose patients in its first pivotal Phase 3 study.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.